Total amount: € 0,00
Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,532
Online ISSN 1827-1715
Sara PAGANI 1, Gianpaolo DE FILIPPO 2, Giulia GENONI 3, Domenico RENDINA 4, Cristina MEAZZA 1, Elena BOZZOLA 5, Gianni BONA 3, Mauro BOZZOLA 1
1 Department of Internal Medicine and Therapeutics, Pediatric and Adolescentology Unit, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2 Pediatric Endocrinology Unit, Gaetano Rummo Hospital, Benevento, Italy; 3 Department of Health's Sciences, Università del Piemonte Orientale, Novara, Italy; 4 Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy; 5 Department of Pediatrics, Bambino Gesù Children Hospital, Rome, Italy
BACKGROUND: No gold standard pharmacological stimulation test exists for the diagnosis of growth hormone deficiency (GHD). In addition, the genetic factors that influence growth hormone (GH) responses remain unclear. This study aimed to determine whether polymorphisms in exon 6 of the GH receptor gene influence responses to the L-arginine GH stimulation test.
METHODS: This study included 27 prepubertal patients with confirmed GHD. GHD was defined as a peak GH level <8 ng/ml in response to pharmacological stimulation. The mean GH peak after L-arginine stimulation was 2.9 ± 2.9 ng/ml.
RESULTS: The included patients had the following genotypes at the third position of codon 168: AA (n=1), AG (n=15) and GG (n=11). Patients carrying the AA and AG genotypes exhibited stronger responses to arginine than patients with the GG genotype (3.1 ± 2.7 vs. 1.5 ± 1.3 ng/ml, p = 0.01).
CONCLUSIONS: The approach employed in this study could elucidate GH profiles under physiological and pathological conditions, facilitating improved interpretation of pharmacological stimulation tests.